ReviewAmerican journal of translational research2021
Meta-analysis of the effects of combination therapies of β-lactams and fluoroquinolones or macrolides in the treatment of community-acquired pneumonia.
Review in American journal of translational research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 citations in OpenAlex.
- Management of pneumonia by the emergency radiologist.European journal of radiology open · 2026Article
- The Global Burden of Community-Acquired Pneumonia in Adults, Encompassing Invasive Pneumococcal Disease and the Prevalence of Its Associated Cardiovascular Events, with a Focus on Pneumolysin and Macrolide Antibiotics in Pathogenesis and Therapy.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe purpose of this study was to identify the optimal treatment plan for hospitalized patients with community-acquired pneumonia (CAP) by evaluating related studies on combination therapies of β-lactams/macrolides (BLM) and β-lactams/fluoroquinolones (BLFQ) in the treatment of CAP.
methodsA meta-analysis was performed on studies with mortality rates as the main result using PubMed, Scopus, Cochrane, and other journal databases. The literature was evaluated using GRADE and MiNORS.
resultsA total of 17 studies were included. Various studies included the effects of combination therapy and mortality rates of β-lactam, fluoroquinolones and macrolides. The quality of currently available evidence was low. In the preliminary data analysis, the mortality rate of BLFQ was higher than that of BLM (RR = 1.33, 95% CI: 1.15-1.54, I
conclusionThe related studies on the relative effects of BLFQ and BLM therapies in the treatment of CAP hospitalized patients have low-quality evidence. The current data indicate that BLFQ combination therapy is associated with higher mortality rates.
Indexed as
Identifiers
34017402PMC8129382W3162065304What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.